Roflumilast reduces the activity of phosphodiesterase-4, a protein that occurs naturally in body cells. A reduction in the activity of this protein leads to reduced inflammation in the lungs. In this way, the narrowing of the airways that occurs in chronic obstructive pulmonary disease (COPD) is reduced. The preparation therefore alleviates existing breathing problems.
Daxas 500ug,90pcs
€412.50
The preparation contains the anti-inflammatory active ingredient roflumilast, which belongs to the group of so-called phosphodiesterase-4 inhibitors.
